Timing of colony-stimulating factors after chemotherapy is about supporting neutrophil recovery after myelosuppression. The first dose is given after chemotherapy, but not immediately; waiting at least 24 hours allows the cytotoxic effects to peak and the marrow to respond to growth signals. It can be given up to about 96 hours (4 days) after chemotherapy, which provides protection during the period when neutrophil counts are most at risk of dropping. Starting too early (immediately) offers little benefit and can complicate management, while waiting much longer would leave patients exposed to febrile neutropenia during the highest-risk window. Therefore, administering the first dose no sooner than 24 hours and within about 96 hours after chemotherapy best optimizes neutrophil recovery and infection protection.

Local reactions at the injection site come from tissue injury and local inflammation where the vaccine is deposited. The intramuscular route places the vaccine into muscle tissue, which has more nerve endings and a robust blood supply. The depth of injection causes more mechanical irritation and a stronger local inflammatory response, leading to soreness, warmth, or a tender lump at the site. Adjuvants and the antigen itself can amplify this local reaction. In contrast, vaccines given by mouth or through the nose bypass a localized tissue injection, so you don’t see an injection-site soreness. Subcutaneous injections do cause some local soreness, but the tissue affected (fat under the skin) typically produces less soreness than muscle, so the strongest local reaction is more commonly associated with the intramuscular route. That’s why IM vaccines are the best answer here.

Guillain-Barré syndrome is an autoimmune attack on the peripheral nerves. It often follows an infection, and the immune system mistakenly targets the myelin or axons of these nerves, causing rapidly progressive weakness that typically starts in the legs and ascends, along with numbness and loss of reflexes. Because the problem lies in the peripheral nervous system, not the brain or spinal cord, it is not a brain infection or a lung viral disease, and it is not an allergic reaction to foods. The underlying mechanism often involves molecular mimicry, where antibodies or immune cells directed at a prior infection cross-react with nerve components, leading to demyelination and sometimes axonal damage. This understanding helps distinguish it from other neurologic disorders and informs treatment approaches such as IVIG or plasmapheresis to modulate the autoimmune response.

Calcineurin inhibitors block a calcium-activated phosphatase needed for T cell activation. They prevent NFAT from driving IL-2 transcription, so T cells don’t proliferate effectively. Cyclosporine achieves this by binding cyclophilin to form a complex that inhibits calcineurin, making it the drug in this list that fits the calcineurin-inhibitor category. The other medications work by different pathways—mycophenolate mofetil blocks purine synthesis; sirolimus inhibits mTOR signaling; azathioprine is a purine analog affecting DNA synthesis. Thus cyclosporine is the drug that fits the calcineurin-inhibitor class.